Equities Analysts Offer Predictions for MNPR FY2029 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Stock analysts at HC Wainwright lifted their FY2029 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn $2.44 per share for the year, up from their prior estimate of $2.41. HC Wainwright currently has a “Buy” rating and a $125.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.82) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2030 earnings at $6.77 EPS.

Other equities analysts have also issued research reports about the company. UBS Group set a $125.00 price objective on Monopar Therapeutics in a report on Thursday, July 23rd. Zacks Research raised Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Cantor Fitzgerald lowered Monopar Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $109.00 to $119.00 in a research report on Thursday. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research note on Tuesday, June 2nd. Finally, Barclays reissued an “overweight” rating and issued a $128.00 price objective (up from $125.00) on shares of Monopar Therapeutics in a report on Thursday. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $117.42.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $110.41 on Friday. Monopar Therapeutics has a 12 month low of $29.18 and a 12 month high of $124.82. The firm has a market capitalization of $739.75 million, a P/E ratio of -50.88 and a beta of 1.47. The company’s fifty day moving average price is $95.04 and its 200 day moving average price is $71.23.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics during the third quarter worth about $28,000. BNP Paribas Financial Markets boosted its stake in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth approximately $65,000. JPMorgan Chase & Co. grew its holdings in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Monopar Therapeutics in the 2nd quarter valued at approximately $80,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.